Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate
Question
Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate
Direct answer
Full enrollment in registrational cohorts locks in the clinical milestone timeline, driving biotech asset repricing for OCS ahead of primary endpoint data. — bullish pressure on OCS via clinical milestone derisking into registrational readout.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-19
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate”, revision 1, evidence through 2026-10-19. https://marketontology.com/catalysts/2026-10-19/oculis-completes-predict-1-registrational-randomization-in-dry-eye-candidate-54ec81
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| OCS | ▲Bull | 1–3 months | clinical milestone derisking into registrational readout | 74 |
Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate
Full enrollment in registrational cohorts locks in the clinical milestone timeline, driving biotech asset repricing for OCS ahead of primary endpoint data. — bullish pressure on OCS via clinical milestone derisking into registrational readout.
Completed randomization of 176 patients in PREDICT-1 trial
- SourceCompleted randomization of 176 patients in PREDICT-1 trial
- TransmissionFull enrollment in registrational cohorts locks in the clinical milestone timeline, driving biotech asset repricing for OCS ahead of primary endpoint data.
- SummaryOculis finalized randomization of 176 patients in its PREDICT-1 registrational study. The study investigates Licaminlimab in TNFR1-driven dry eye disease. Sixty-six percent of the cohort possesses the biomarker variant correlated with therapeutic efficacy.
- OCSDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- OCS closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- OCS price vs. pre-event level
- OCS volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-20Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMSOCS
- 2026-10-20Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMSOCS
- 2026-10-07Oculis to present Licaminlimab at AAO ahead of PREDICT-1 trial readout around year-endOCS
- 2026-10-07Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 ReadoutOCS
- 2026-10-07Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readoutOCS
- 2026-10-07Oculis to Present Licaminlimab Data Ahead of Year-End Registrational ReadoutOCS
- 2026-10-07Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readoutOCS
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.